HK1204988A1 - Methods and compositions for preventing or treating ophthalmic conditions - Google Patents

Methods and compositions for preventing or treating ophthalmic conditions

Info

Publication number
HK1204988A1
HK1204988A1 HK15105911.8A HK15105911A HK1204988A1 HK 1204988 A1 HK1204988 A1 HK 1204988A1 HK 15105911 A HK15105911 A HK 15105911A HK 1204988 A1 HK1204988 A1 HK 1204988A1
Authority
HK
Hong Kong
Prior art keywords
compositions
preventing
methods
ophthalmic conditions
treating ophthalmic
Prior art date
Application number
HK15105911.8A
Other languages
English (en)
Chinese (zh)
Inventor
Wilson D Travis
Mooney K George
Peter J Oates
Original Assignee
Stealth Peptides Internat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Internat Inc filed Critical Stealth Peptides Internat Inc
Publication of HK1204988A1 publication Critical patent/HK1204988A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15105911.8A 2012-02-22 2015-06-22 Methods and compositions for preventing or treating ophthalmic conditions HK1204988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601878P 2012-02-22 2012-02-22
US201261605576P 2012-03-01 2012-03-01
PCT/US2013/027175 WO2013126597A1 (en) 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
HK1204988A1 true HK1204988A1 (en) 2015-12-11

Family

ID=49006208

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105911.8A HK1204988A1 (en) 2012-02-22 2015-06-22 Methods and compositions for preventing or treating ophthalmic conditions

Country Status (8)

Country Link
US (3) US20150018288A1 (de)
EP (4) EP2817018A4 (de)
JP (3) JP2015509500A (de)
CN (2) CN105343869A (de)
AU (3) AU2013222423A1 (de)
CA (1) CA2865317A1 (de)
HK (1) HK1204988A1 (de)
WO (1) WO2013126597A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2961420T3 (da) 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
EP3673913A1 (de) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Verbindungen zur behandlung von mitochondrialen erkrankungen
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017781A1 (en) * 2013-08-01 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating leber's hereditary optic neuropathy
EP3087093B1 (de) 2013-12-27 2021-11-10 Stealth Biotherapeutics Corp Pharmazeutisch relevante aromatisch-kationische peptide
CA2936146A1 (en) * 2014-01-06 2015-07-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
BR112016020181A8 (pt) 2014-03-03 2021-06-29 Encore Vision Inc composições de ácido lipoico éster colina e métodos de uso.
CA2942143A1 (en) * 2014-03-03 2015-09-11 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides and methods of generating the same
CN113831392A (zh) 2015-03-06 2021-12-24 康德生物医疗技术公司 制备药物相关肽的方法
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
EP3606938A1 (de) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Kristalline salzformen von boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
EP3921420A4 (de) * 2019-02-08 2022-11-16 Ohio State Innovation Foundation Arzneimittelabgabezusammensetzungen zur okularen verabreichung von therapeutika und verwendungsverfahren dafür
EP3771467A1 (de) * 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 zur prävention und behandlung von aneurysmen
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
WO2023279067A1 (en) * 2021-07-01 2023-01-05 The Regents Of The University Of California Targeting piezo1 to treat inherited and age-related macular degenerations
CN113975402B (zh) * 2021-07-19 2023-05-16 河南大学 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用
IL312199A (en) * 2021-10-20 2024-06-01 Stealth Biotherapeutics Inc Methods and compositions containing peptide erasers for treating, preventing, delaying, ameliorating or delaying the onset of ocular conditions
CN115252555B (zh) * 2022-06-07 2023-11-21 西安电子科技大学 一种膜融合性脂质体、制备方法及其在蛋白质递送中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US781405A (en) 1903-09-03 1905-01-31 Marcus A Coykendall Blank for dental plates.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002506028A (ja) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
US7550439B2 (en) * 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3549594A1 (de) * 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatisch-kationisches peptid zur verwendung in einem verfahren zur reduzierung der cd36-expression
EP2209371B1 (de) * 2007-10-19 2017-01-04 SARcode Bioscience Inc. Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP3272353A1 (de) * 2008-02-07 2018-01-24 Cornell University Verfahren zur vorbeugung oder behandlung von insulinresistenz
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
EP3741381B1 (de) * 2008-02-26 2024-04-24 Cornell University Peptide zur verwendung zur prävention oder behandlung von akutem nierenversagen
EP4302829A3 (de) * 2009-08-24 2024-03-27 Stealth BioTherapeutics Inc. Peptid zur verwendung bei der vorbeugung oder behandlung von makula degenerationugenleiden
AU2010325908A1 (en) * 2009-12-04 2012-06-07 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
EP2590664B1 (de) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Verfahren zur vorbeugung oder behandlung eines fehlenden refluxes nach einer ischämie- oder reperfusionsverletzung

Also Published As

Publication number Publication date
WO2013126597A1 (en) 2013-08-29
AU2019203713A1 (en) 2019-06-20
CA2865317A1 (en) 2013-08-29
EP2817018A1 (de) 2014-12-31
JP2015509500A (ja) 2015-03-30
EP3479839A1 (de) 2019-05-08
AU2013222423A1 (en) 2014-09-11
US20160361377A1 (en) 2016-12-15
CN105343869A (zh) 2016-02-24
EP3281634A1 (de) 2018-02-14
US20180296630A1 (en) 2018-10-18
CN104244964A (zh) 2014-12-24
AU2017254849A1 (en) 2017-11-16
JP2019034947A (ja) 2019-03-07
EP2817018A4 (de) 2015-09-23
JP2017214380A (ja) 2017-12-07
EP3078384A1 (de) 2016-10-12
US20150018288A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
IL278018A (en) Methods for the treatment or prevention of ophthalmological conditions
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
IL269166A (en) Methods and preparations for treating inflammation
HK1251796A1 (zh) 治療糖尿病的方法和組合物
HK1215170A1 (zh) 治療精神分裂症的方法和組合物
EP2830637A4 (de) Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit oxidativem stress
DK3292875T3 (en) Compositions and methods for treating diseases
HK1206266A1 (en) Methods and compositions for the prevention and treatment neuropathy
HK1208598A1 (en) Methods and compositions for treating pain
SI2893019T1 (sl) siRNA IN NJENA UPORABA V POSTOPKIH IN SESTAVKIH ZA ZDRAVLJENJE IN/ALI PREPREČEVANJU OBOLENJ OČI
HK1210163A1 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
HK1202260A1 (en) Agent for preventing and or treating veisalgia